Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2017 (pdf):
download in single page format - double page (broad) format

Publication overview

Current news and events

Computer simulated cancer treatment presented in research magazine Apollo

Arnoldo Frigessi (photo: Ola Sæther)

Researchers at the Oslo University Hospital and University of Oslo are developing a computer program that can assist oncologists to find the best personalized treatment for each patient. The main driving force behind the project is Arnoldo Frigessi, professor in medical statistics at UiO, who is head of the "Oslo Centre for Biostatistics Epidemiology" at OUS and leader of the "Centre for Research-based Innovation" (SFI) "Big Insight".

The award winning research magazine "Apollon" recently presented the work of Frigessi and collaborators in an extensive feature article by Yngve Vogt.

Nature Communications publication:How Natural Killer Cells Remember their Education

Karl-Johan Malmberg,
Senior author

A joint effort by several groups at the Institute for Cancer Research and University of Oslo, led by Dr. Jodie Goodridge and Prof. Karl-Johan Malmberg provide new insights into the molecular basis behind NK cell education.

NK cells calibrate their functional potential against host MHC in a process termed education. Paradoxically, the more inhibitory input the cell receives during its education, the stronger its functional potential. Although this phenomena is well documented and conserved across species, the cellular and molecular mechanisms underlying NK cell education have remained elusive. 

Funding from FRIPRO to five promising researchers from Oslo University Hospital

Anita Sveen (left) and Kaisa Haglund are among the supported researchers

FRIPRO is an open, national competitive arena that covers all fields of research. FRIPRO aims to promote scientific excellence, bold and innovative research, support the careers of young research talents, as well as increasing the mobility for scientists early in their careers.

Five promising researchers and projects originating from Oslo University Hospital have now been granted suppoert from FRIPRIO.

Research at Oslo University Hospital basis for international drug development initiative between Norway and India

Kjetil Taskén (left) and Ivar Sjaastad
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA  Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.

Units and subpages

View all subunitsHide all subunits